迈威生物港股IPO获中国证监会备案

Group 1 - The core point of the news is that Maiwei Biotech plans to issue up to 62,664,600 overseas listed ordinary shares and list on the Hong Kong Stock Exchange, with the China Securities Regulatory Commission issuing a notification for the overseas listing registration [1] - Maiwei Biotech focuses on the development of drugs for tumors and age-related diseases, with a competitive and multi-tiered product pipeline that includes over 10 drug assets across various fields such as immunology, ophthalmology, and orthopedics [3] - In the third quarter of 2025, Maiwei Biotech reported a revenue of 465 million yuan, representing a year-on-year increase of 1717.41%, while the net profit attributable to shareholders was a loss of 46.34 million yuan [3] Group 2 - For the first three quarters of 2025, the company achieved a revenue of 565 million yuan, showing a year-on-year growth of 301.03%, but reported a net loss of 598 million yuan attributable to shareholders [3]